I-Tien Yeh1, Carolyn Mies. 1. Department of Pathology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229, USA. yehi@uthscsa.edu
Abstract
CONTEXT: Immunohistochemistry has an expanding role in mammary pathology that has been facilitated by a growing list of available antibodies and a better understanding of biology. OBJECTIVE: To explore the key role of immunohistochemistry in guiding adjuvant therapy decisions and sentinel node staging in breast cancer, as well as the role of immunohistochemistry as an aid to distinguishing usual ductal hyperplasia from atypical ductal hyperplasia/low-grade carcinoma in situ; subtyping a carcinoma as ductal or lobular, basal or luminal; ruling out microinvasion in extensive intraductal carcinoma; distinguishing invasive carcinoma from mimics; and establishing that a metastatic carcinoma of unknown primary site has originated in the breast. DATA SOURCES: Current literature is reviewed, including clinical and pathologic journals. CONCLUSIONS: As new, targeted treatments for breast cancer are developed, pathologists can expect additional immunohistochemistry applications in the future.
CONTEXT: Immunohistochemistry has an expanding role in mammary pathology that has been facilitated by a growing list of available antibodies and a better understanding of biology. OBJECTIVE: To explore the key role of immunohistochemistry in guiding adjuvant therapy decisions and sentinel node staging in breast cancer, as well as the role of immunohistochemistry as an aid to distinguishing usual ductal hyperplasia from atypical ductal hyperplasia/low-grade carcinoma in situ; subtyping a carcinoma as ductal or lobular, basal or luminal; ruling out microinvasion in extensive intraductal carcinoma; distinguishing invasive carcinoma from mimics; and establishing that a metastatic carcinoma of unknown primary site has originated in the breast. DATA SOURCES: Current literature is reviewed, including clinical and pathologic journals. CONCLUSIONS: As new, targeted treatments for breast cancer are developed, pathologists can expect additional immunohistochemistry applications in the future.
Authors: Marie N Nickelsen; Sarah VON Holstein; Alastair B Hansen; Jan U Prause; Steffen Heegaard Journal: Oncol Lett Date: 2015-05-27 Impact factor: 2.967
Authors: Werner Boecker; Göran Stenman; Tina Schroeder; Udo Schumacher; Thomas Loening; Lisa Stahnke; Catharina Löhnert; Robert Michael Siering; Arthur Kuper; Vera Samoilova; Markus Tiemann; Eberhard Korsching; Igor Buchwalow Journal: Virchows Arch Date: 2017-03-16 Impact factor: 4.064
Authors: Mine Mumcuoglu; Sevgi Bagislar; Haluk Yuzugullu; Hani Alotaibi; Serif Senturk; Pelin Telkoparan; Bala Gur-Dedeoglu; Burcu Cingoz; Betul Bozkurt; Uygar H Tazebay; Isik G Yulug; K Can Akcali; Mehmet Ozturk Journal: PLoS One Date: 2010-06-24 Impact factor: 3.240
Authors: Katrina N Glazebrook; Katie N Jones; Christina A Dilaveri; Kyle Perry; Carol Reynolds Journal: Cancer Imaging Date: 2011-06-29 Impact factor: 3.909